Envestnet Portfolio Solutions Inc. Has $216,000 Position in Bruker Corporation (NASDAQ:BRKR)

Envestnet Portfolio Solutions Inc. lessened its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 70.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,181 shares of the medical research company's stock after selling 12,436 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Bruker were worth $216,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its position in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after buying an additional 196 shares during the last quarter. Insigneo Advisory Services LLC raised its stake in shares of Bruker by 4.7% in the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock valued at $286,000 after purchasing an additional 218 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after purchasing an additional 222 shares in the last quarter. CGN Advisors LLC raised its stake in shares of Bruker by 1.4% in the 1st quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock valued at $919,000 after purchasing an additional 296 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in shares of Bruker by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 48,011 shares of the medical research company's stock valued at $2,814,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Insider Buying and Selling

In related news, CEO Frank H. Laukien bought 2,608 shares of Bruker stock in a transaction dated Friday, June 6th. The shares were bought at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the transaction, the chief executive officer owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 27.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

BRKR has been the topic of several research reports. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. UBS Group reduced their price objective on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Stifel Nicolaus decreased their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a report on Thursday, May 8th. The Goldman Sachs Group decreased their price target on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Finally, Citigroup lowered Bruker from a "strong-buy" rating to a "hold" rating and lowered their target price for the stock from $50.00 to $40.00 in a report on Thursday, May 22nd. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $52.89.

Bruker Stock Performance

Shares of NASDAQ:BRKR traded down $0.04 on Friday, hitting $42.42. 1,207,758 shares of the company were exchanged, compared to its average volume of 1,708,257. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. The company's 50 day moving average price is $38.95 and its two-hundred day moving average price is $46.03. Bruker Corporation has a one year low of $34.10 and a one year high of $72.94. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of 81.58, a PEG ratio of 2.85 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. The business had revenue of $801.40 million for the quarter, compared to analyst estimates of $763.83 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The firm's revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 EPS. Research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were given a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.47%. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.